Another Pharma CEO Bites the Dust! Posted: September 12, 2006 Bristol-Myers Squibb Chief Executive Peter Dolan will leave the company effective immediately, according to a Wall Street Journal report just published. The BMS board had several good reasons for firing Dolan. Although they may have had no choice, which one do you think was most important to the board if the choice was up to them? You can read more about this along with excerpts from the WSJ report in today's post to Pharma Marketing Blog. For more posts in related topic areas, see: Drug Companies Pharma CEOs and Big Wigs If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe. Enter your Email Address | Return to Pharma Marketing Blog Topics |

Which issue rankled the BMS board most? Dolan's handling of Apotex Loss of 60% of BMS's stock value Neither of these issues bothered the board Both were equally important